ClinicalTrials.gg
RecruitingNCT06642792Updated Feb 11, 2025

A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

A Phase 1/2 interventional study of AK129 and AK117 in Classic Hodgkin Lymphoma, sponsored by Akeso. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-11.

Sponsored by Akeso · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
280
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 57 studies in Hodgkin Disease with a site in China — 28 open to participants now, 31 under way, 3 of them phase 3. Hodgkin Disease · China.

Planned enrollment
2nd of 53
280 · median 75
Started
2025
with 2 others
Phase 1/2
10 of 57
5 open now
Primary completion
2027-11
later than 23 of 30 live
Registered
51st of 57
by date
Lead sponsor
3 of 57
Akeso

Among the 57 studies in Hodgkin Disease with a site in China, this one is the 2nd largest by planned enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2025, is one of 10 in phase 1/2, reaches primary completion later than 23 of the 30 other live ones, and was the 51st registered.

Hodgkin Disease

1,384 studies on the registry are indexed under Hodgkin Disease; 161 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

28 of the 57 studies in Hodgkin Disease with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 134 Hodgkin Disease studies recruiting now, 71 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Hodgkin Disease with a site in China, or all of them as a file.
02

Study summary

This is a phase I/II study. All subjects are patients diagnosed with relapse or refractory (R/R) classic Hodgkin lymphoma (cHL) and has progressed on treatment with PD-1/L1 inhibitor therapy. The purpose of this study is to evaluate the safety and efficacy of AK129 (bispecific antibody targeting LAG-3 and PD-1) monotherapy or in combination with AK117 (anti-CD47 monoclonal antibody) in R/R cHL with PD-1/L1 inhibitor treatment failure.

03

Conditions studied

  • Classic Hodgkin Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old at the time of enrolment.
  • (ECOG) performance status of 0 or 1.
  • Expected Survival of ≥ 12 weeks.
  • Diagnosed as R/R cHL according to Lugano 2014 criteria.
  • Has progressed on treatment with /L1 inhibitior therapy.
  • Has adequate organ function.
  • All female and male subjects of must agree to use an effective method of from the start of screening until 120 days after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) or gray zone lymphoma.
  • Central nervous system (CNS) lymphoma involvement.
  • Known history of human T-cell leukemia virus type 1 (HTLV-1) infection.
  • hematopoietic stem cell transplantation (auto-HSCT) or chimeric antigen receptor T cell immunotherapy (CAR-T) within 90 days prior to the first dose of study treatment.
  • Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  • Previous use of any agents targeting the 7-SIRPα pathway, LAG-3 pathway, or similar targets.
  • Has other within 3 years prior to the first dose or residual lesions from other malignancies diagnosed more than 3 years ago.
  • Has an active disease requiring systemic treatment within 2 years prior to the first dose.
  • History of active or previously confirmed inflammatory bowel disease.
  • History of interstitial lung disease requiring therapy, or current interstitial lung disease.
  • Has known active or .
  • Unresolved toxicity from previous anti-tumor treatment.
  • Uncontrolled comorbidities.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    AK129

    Phase Ia: Subjects will receive AK129: different doses on every 2 weeks.

    Drug: AK129

  • Experimental
    AK129+AK117

    Phase Ib: Subjects will receive: AK129: different doses on every 2 weeks, AK117: 30mg/kg on every 2 weeks. Phase II: Subjects will receive: AK129: recommended phase II dose (RP2D) from phase Ib on every 2 weeks, AK117: 30mg/kg on every 2 weeks.

    Drug: AK129 · Drug: AK117

Interventions

  • DrugAK129

    Subjects receive AK129 intravenously.

  • DrugAK117

    Subjects receive AK117 intravenously.

06

What researchers measure

Primary outcomes

  1. Phase I: Number of participants with dose limiting toxicity (DLT)

    Any untoward medical occurrence in a subject within the first 28 days following the first dose, considered related to the study treatment.

    Time frame: Within the first 28 days following the first dose of study treatment.

  2. Phase I/II: Incidence and severity of adverse events (AEs)

    Any untoward medical occurrence in a subject, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Up to approximately 2 years.

  3. Phase I/II: Objective response rate (ORR)

    The proportion of subjects achieving complete response (CR) or partial response (PR) assessed by investigator per Lugano 2014 criteria.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Disease control rate (DCR)

    The proportion of subjects achieving complete response (CR) , partial response (PR) or stable disease (SD) assessed by investigator per Lugano 2014 criteria.

    Time frame: Up to approximately 2 years

  2. Time to response (TTR)

    The time from cycle 1 day 1(C1D1) to the first recorded response assessed by investigator per Lugano 2014 criteria.

    Time frame: Up to approximately 2 years

  3. Duration of response (DoR)

    The time from the first recorded response until disease progression assessed by investigator or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years

  4. Progression-free survival (PFS)

    The time from C1D1 until disease progression assessed by investigator or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years

  5. Overall survival (OS)

    The time from C1D1 until death due to any cause.

    Time frame: Up to approximately 2 years

  6. Maximum concentration (Cmax)

    The maximum concentration of the drug observed in the blood plasma after administration.

    Time frame: Up to approximately 2 years

  7. Time to maximum concentration (Tmax)

    The time taken to reach the maximum concentration (Cmax) of the drug in the blood plasma.

    Time frame: Up to approximately 2 years

  8. Area under the curve (AUC)

    The area under the plasma concentration versus time curve, which represents the total drug exposure over time.

    Time frame: Up to approximately 2 years

  9. Half-life (T1/2)

    The time required for the plasma concentration of the drug to decrease by half.

    Time frame: Up to approximately 2 years

  10. Anti-drug antibody (ADA)

    Number of subjects with detectable anti-drug antibodies.

    Time frame: Up to approximately 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Nov 2027, 34 months after the start.

Of 63 phase 1/2 interventional studies under Hodgkin Disease, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 53 and three quarters within 97. This study's planned 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2024
First posted
Oct 15, 2024
StartActual
Jan 17, 2025
Primary completionEst.
Nov 2027
CompletionEst.
Feb 2028
Last update
Feb 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06642792
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Jan 17, 2025
Primary completion
Nov 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Feb 11, 2025

Study contacts

Wenting Li, MD
Contact
clinicaltrials@akesobio.com
+86(0760)89873999
Wenting Li, MD
study director · Akeso

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/LAG-3 Bispecific Antibody AK129

Start the discussion